Soligenix, Inc. (SNGX) Tuesday announced positive data from a comparability study evaluating its HyBryte versus Valchlor in the treatment of cutaneous T-cell lymphoma (CTCL).
HyBryte is an ointment containing photosensitizer hypericin proposed to treat CTCL. Ceptaris Therapeutics' Valchlor is an approved treatment for mycosis fungoides-type cutaneous T-cell lymphoma.
In the comparative study, 60 percent of patients treated with HyBryte achieved 50 percent or more improvement in their mCAILS (modified Composite Assessment of Index Lesion Severity) score after 12 weeks, versus 20 percent treated with Valchlor.
"These results support the positive HyBryte data from the previously completed Phase 3 FLASH study and demonstrates that a relatively short treatment period with the drug can result in clinically meaningful outcomes," stated Christopher J. Schaber, President and Chief Executive Officer of Soligenix.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.